SCHEMBL25252935

SCHEMBL25252935

CN(C)C(=O)c1cc(Br)c(NC(=O)C(F)(F)F)c([N+](=O)[O-])c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.39
HTT P42858 1/20 0.39
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
MEN1 O00255 2/20 0.35
HPGD P15428 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
ERN1 O75460 2/20 0.35
ABL1 P00519 1/20 0.35
AR P10275 3/20 0.34
PGR P06401 1/20 0.34
CYP3A4 P08684 1/20 0.34
MAPT P10636 3/20 0.34
POLB P06746 1/20 0.34
HCAR3 P49019 1/20 0.34
GAA P10253 2/20 0.34
PDK1 Q15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25250177 0.86 KMT2A (0.40) KMT2AHTTALDH1A1LMNASMN1; SMN2
SCHEMBL25250002 0.85 MAPT (0.44) KMT2AHTTALDH1A1LMNASMN1; SMN2
SCHEMBL29809179 0.85 MAPT (0.44) KMT2AHTTALDH1A1LMNASMN1; SMN2
SCHEMBL1967675 0.84 ABL1 (0.48) KMT2AHTTALDH1A1LMNASMN1; SMN2
SCHEMBL31123059 0.81 ALDH1A1 (0.48) KMT2AHTTALDH1A1LMNASMN1; SMN2
SCHEMBL5218577 0.80 KMT2A (0.49) KMT2AALDH1A1LMNASMN1; SMN2NPC1
SCHEMBL29181806 0.79 MEN1 (0.44) KMT2AALDH1A1LMNASMN1; SMN2NPC1
SCHEMBL25298464 0.74 ALDH1A1 (0.51) KMT2AHTTALDH1A1LMNAMEN1
SCHEMBL29809012 0.74 ALDH1A1 (0.51) KMT2AHTTALDH1A1LMNAMEN1
SCHEMBL25834987 0.73 AR (0.36) KMT2AHTTALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250051287-A1 METHOD FOR PREPARATION OF BENZIMIDAZOLE DERIVATIVES HK INNO.N CORPORATION (KR) 2025-02-13 US disclosed
CN-116354889-B Process for preparing benzimidazole derivatives 怡诺安有限公司 2025-01-14 CN disclosed
EP-4457216-A1 METHOD FOR PREPARATION OF BENZIMIDAZOLE DERIVATIVES HK inno.N Corporation (KR) 2024-11-06 EP disclosed
WO-2023128525-A1 METHOD FOR PREPARATION OF BENZIMIDAZOLE DERIVATIVES HK INNO.N CORPORATION (KR) 2023-07-06 WO disclosed
CN-116354889-A Process for preparing benzimidazole derivatives 怡诺安有限公司 2023-06-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051287-A1 METHOD FOR PREPARATION OF BENZIMIDAZOLE DERIVATIVES CYP3A4, CYP3A5, TMBIM6 KMT2A 1897/4885HTT 3576/4885ALDH1A1 571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.